Metformin vs. Ozempic: Weight Loss, Cost, and Whether to Take Both

Metformin vs Ozempic: which one actually helps you lose weight?

No trial has put these two drugs head to head. Any comparison sets two separate bodies of research side by side. Semaglutide, the drug in Ozempic, was tested at its full weight-loss dose in the STEP 1 trial. People lost close to 15% of their body weight on average over 68 weeks.

Ozempic's own top dose is lower than that trial dose. So people taking Ozempic off-label for weight tend to lose less than that headline figure, even though it's the same molecule. Off-label means using a drug for something the FDA didn't approve it for.

Metformin has never produced anything close on its own. Most of its trials were in women with PCOS or type 2 diabetes. The average effect is modest, a few pounds at most. Many studies find metformin close to weight-neutral alone, with a clearer benefit only alongside diet changes. That's not a flaw. It simply wasn't built to move weight the way an appetite-quieting GLP-1 is.

What each drug does for blood sugar and insulin resistance

Metformin, approved in the mid-1990s, works mostly on the supply side of blood sugar. It tells the liver to release less glucose into the blood. It also makes muscle and fat cells respond better to the insulin you already have. That is what improving insulin resistance means in practice.

Because metformin doesn't push the pancreas to release extra insulin, it rarely causes low blood sugar on its own. That's part of why it's prescribed so widely.

Ozempic pulls a different lever. Semaglutide mimics GLP-1, a hormone your gut makes after eating. It releases insulin only when blood sugar is high, slows how fast your stomach empties and quiets hunger signals in the brain. The FDA approved Ozempic in 2017 for adults with type 2 diabetes. Metformin adjusts machinery already running in the background, while Ozempic changes how much you eat.

Can you take metformin and Ozempic together?

Yes, and it's a well-established pattern. Several of the trials behind Ozempic's approval, including SUSTAIN 2, 3, 4 and 10, enrolled people already taking metformin and kept them on it. A good share of the evidence for semaglutide comes from people using both drugs at once.

In practice, prescribers often keep metformin as the steady daily baseline for insulin sensitivity. They then add a GLP-1 on top for appetite and weight. Metformin carries little risk of low blood sugar on its own, so the pair is usually well tolerated on that front. Stomach side effects can add up, though, as covered below.

How much does each one cost, and why is the gap so big?

Metformin is close to the cheapest prescription drug in the country. It has been a generic, made by many companies, for decades. That's why Walmart can sell it on its $4 generics list. With a free SingleCare coupon, 60 tablets of 500 mg start at about $5.

The extended-release version costs more at every pharmacy, but still a fraction of any GLP-1. Insurance barely changes the math. Metformin sits on the lowest tier of nearly every drug list, and plans rarely restrict a drug this cheap.

Ozempic is the opposite. It's a patented brand-name drug, and insurance coverage is tied to its type 2 diabetes label. Its list price is about $1,000 a month, set to drop to $675 on January 1, 2027. Novo Nordisk's own self-pay prices are much lower:

• Ozempic pill, formerly Rybelsus: about $150 a month at the lowest dose, up to about $300
• Ozempic pen: about $350 a month up to 1 mg, and about $500 at 2 mg
• New patients on the pen: the first two fills cost about $200 each, through December 31, 2026

With commercial insurance that covers Ozempic, the NovoCare savings card can bring it to as little as $25 a month. It takes off at most $100 a month. A prescription for weight loss or PCOS alone usually won't get covered in the first place.

On Medicare, Part D plans cover Ozempic for type 2 diabetes. The savings card doesn't apply, and the Medicare GLP-1 Bridge doesn't include Ozempic. Our full Ozempic cost breakdown walks through every route, compounded semaglutide included.

Side effects: metformin's stomach issues vs Ozempic's

Both drugs can upset your stomach, but in different ways. Metformin's issues are mostly a first-weeks problem: diarrhea, nausea and a metallic taste. They usually ease as your body adjusts. Switching to the extended-release version often helps.

Metformin's rare but serious risk is lactic acidosis, a dangerous acid buildup in the blood linked to weak kidneys. The FDA advises against starting it when kidney function, measured as eGFR, is between 30 and 45. It must not be used below 30. That's why a kidney blood test comes before the first prescription.

Ozempic's stomach symptoms, nausea, vomiting, diarrhea and constipation, come from the same slowed digestion that makes it work. Up to about one in five people feel nausea at some point, usually right after a dose increase. The fuller picture of Ozempic's side effects covers what's temporary and what needs a call. Taking both drugs means counting both symptom lists, not just the newer one.

Who can actually get each one prescribed?

This difference may matter more than the science for many women. Metformin is FDA-approved for type 2 diabetes. It has been prescribed off-label for insulin resistance and PCOS for decades. No drug is FDA-approved for PCOS itself, and metformin filled that gap because it's cheap, well understood and easy to start.

Getting it takes a routine visit and a kidney blood test. Prescribers rarely hesitate, and insurers rarely fight a drug this cheap.

Ozempic is a different conversation. It's approved only for type 2 diabetes, so using it for insulin resistance or PCOS alone is off-label. Insurers push back hard. A chart that says insulin resistance or PCOS, not type 2 diabetes, is often denied. A drug with a $1,000 list price draws far more scrutiny than one that costs $4.

Is it different for PCOS or perimenopause insulin resistance?

Falling, swinging estrogen in perimenopause worsens insulin resistance and moves fat toward the belly. The mechanism is covered in what causes perimenopause weight gain. For a woman who carried PCOS into her 40s, that shift often worsens an existing pattern. That's exactly when prescribers reach for metformin first, given its long track record in PCOS.

GLP-1 research in PCOS is newer and thinner. Most finished trials pairing a GLP-1 with metformin in PCOS used liraglutide, an older GLP-1, not semaglutide. Those trials generally found the pair beat metformin alone on weight and insulin markers. Semaglutide trials in women with PCOS are underway but not finished. So the evidence for combining metformin with Ozempic in PCOS is still catching up with practice.

Which one is right for you? Verdict by profile

• Insulin resistance or PCOS without type 2 diabetes, on a tight budget: metformin is the realistic start. It's cheap, tolerated by most people, and easy to get prescribed.
• Your main goal is meaningful weight loss: Ozempic, or Wegovy, its weight-loss sibling, has far stronger evidence. Metformin alone won't get you there.
• Your prescriber suggested both: that's a legitimate plan backed by evidence, not a sign metformin failed. Many GLP-1 trials ran on top of metformin.
• You have reduced kidney function: metformin may need a lower dose or be ruled out, depending on your eGFR.
• Metformin's stomach side effects were hard: ask about the extended-release version before giving up on it. If that fails too, other options, GLP-1s included, are worth discussing.
• Not sure medication is the next step: read the order of operations for perimenopause weight loss first.